Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts

07-Dec-2011 - Switzerland

Novartis will showcase more than one hundred and sixty presentations on data from its oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) will feature data presentations from Phase III studies of Afinitor® (everolimus) tablets for investigational uses and Zometa® (zoledronic acid) 4mg/5mL Injection, as well as early-stage studies of the investigational drug BKM120, an inhibitor of PI3K, a key cancer pathway.

The American Society of Hematology (ASH) annual meeting in San Diego will showcase key data for Tasigna® (nilotinib), Exjade® (deferasirox) and the investigational drug INC424 (ruxolitinib). Several early-stage studies will also be presented, including everolimus in Hodgkin lymphoma and Waldenström's macroglobulinemia and LBH589 (panobinostat) in relapsed and bortezomib (BTZ)-refractory multiple myeloma.

"These important data are examples of our research and development strategy to focus on significant unmet medical needs by targeting the fundamental mechanisms of disease," said Hervé Hoppenot, President, Novartis Oncology. "Through our collaborations with the scientific and patient communities, we continue to advance our goal of transforming patients' lives."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance